What GLP-1 drugs do beyond weight loss

Beyond weight loss, the strongest evidence for GLP-1 drugs covers the heart, the blood vessels and the kidneys, and almost all of it comes from people who already have type 2 diabetes or obesity.

GLP-1 receptor agonists, the class that includes semaglutide and liraglutide, copy glucagon-like peptide-1, a hormone the gut releases after a meal [10]. It prompts the pancreas to release insulin, the hormone that clears sugar from the blood, slows how fast the stomach empties and reduces appetite [8], [15]. The recurring theme across these papers is that the same signal reaches the heart, kidneys, liver, nerves and immune cells, not just blood sugar [2], [14], [15].

The cardiovascular evidence is the most developed. Reviews of the large outcome trials, which tracked patients for years and counted heart attacks and strokes, report lower blood pressure, better blood fats and slower atherosclerosis, the build-up of fatty plaque that narrows and stiffens arteries [8].

A related line of work points to healthier behaviour in the cells lining blood vessels, where oxidative stress and inflammation do much of the damage [11].

A 2026 review of stroke prevention reports that longer-acting GLP-1 drugs were linked with 15% to 39% lower stroke risk across the major trials, all of them in people with type 2 diabetes [3]. That is a relative figure: a stroke was somewhere between about a seventh and two-fifths less likely, though the review does not say how many strokes that avoids per 1,000 people treated. Shorter-acting versions of these drugs showed little benefit for the brain's blood supply, and the trials did not all point the same way [3].

Kidney findings run in the same direction but rest on weaker ground. In diabetic mice, and in rats with damaged kidneys and no diabetes, liraglutide lowered kidney inflammation and markers of damage in a way that did not depend on blood sugar [10]. A second study reported that semaglutide reduced diabetic kidney injury by blocking ferroptosis, a form of cell death driven by iron and damaged fats, in laboratory cells, animals and patients [7].

Brain and mental health results are the least settled. Reviews describe possible protection in Alzheimer's disease, Parkinson's disease, depression, anxiety, binge eating and substance use, but human trials have returned mixed results for memory and movement, and the psychiatric studies were small, short and hard to compare with one another [1], [4].

Three further effects are reported, but only in reviews and single studies:

• fatty liver disease of the kind that comes with metabolic problems, where GLP-1 drugs reduced fat and scarring in the liver [5], [6]
• polycystic ovary syndrome, a hormonal condition affecting the ovaries [5]
• diabetic retinopathy, damage to the small blood vessels at the back of the eye [12]

The thread running through these papers is inflammation. Long-running, low-level inflammation turns up in metabolic, heart, kidney, liver and brain disease, and GLP-1 drugs appear to damp it down: they reduce inflammatory messenger molecules called cytokines and change the behaviour of immune cells, including macrophages, which clear debris in tissue, and microglia, their counterpart in the brain [6].

Blood vessels carry GLP-1 receptors on several cell types, among them the endothelial cells that line the vessel wall and help control how it widens, clots and inflames. In laboratory and animal work, GLP-1 signalling improved how those cells behave, calmed inflammation in nearby immune cells and limited overgrowth of the muscle in the vessel wall - three of the steps that build arterial plaque [8], [11].

In the kidney the effect looks at least partly independent of blood sugar. Liraglutide turned down a receptor that senses sugar-damaged proteins and drives inflammation, and shifted kidney cells towards repair rather than damage in mice [10]. Semaglutide acted through a protein called beta-Klotho to reduce iron-driven cell death, and with it inflammation and scarring [7].

Appetite appears to run along a separate route. A 2022 laboratory study traced the effect of gut GLP-1 on eating and stomach emptying to intestinofugal neurons, nerve cells in the gut wall that send signals outward to nerve clusters in the abdomen and on to the brain [9].

All of this is mechanism, not outcome. Most of it was measured in cells and animals, and a pathway that looks protective in a mouse kidney does not by itself mean fewer people end up on dialysis.

The papers behind this article are mostly narrative reviews - expert summaries of a field rather than systematic counts of every trial - alongside animal experiments, cell studies and mechanism work. One of those reviews states that its authors used AI tools to help gather and analyse the literature [5]. That is enough to describe a direction of travel, not to settle a question.

The evidence is also uneven by organ. Heart and kidney conclusions draw on trials that counted events in people; claims about memory, mood, Parkinson's disease and lifespan do not [1], [4]. Stroke results varied with the drug used, kidney function, how long a person had had diabetes and their starting level of risk [3].

Who this evidence does not cover:

• healthy people of normal weight taking these drugs in the hope of living longer, a use none of these studies tested
• children and teenagers, who are not represented in these papers
• anyone after a lifespan claim: no study here measured human lifespan or healthspan, and the paper that discusses expanding healthy lifespan argues a case rather than reporting a trial [14]

None of these papers is a safety analysis. Nothing here describes side effects, who should avoid these drugs, or what happens when someone stops taking them - questions that belong with a doctor holding the person's full history, not with a summary of mechanism papers.

A useful filter for the headlines is to ask what a study actually counted.

If it counted events in people - strokes, hospital admissions, kidney decline - the finding carries weight. If it counted a protein level, a signal inside a cell, or a change in a mouse, it is a lead rather than a result.

Applied to GLP-1 drugs, that filter puts heart and kidney outcomes in the first group, and mood, memory, Parkinson's disease and lifespan in the second.